S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
CGC   21.88 (-1.93%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
CGC   21.88 (-1.93%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
CGC   21.88 (-1.93%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
AAPL   313.05 (-2.26%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
CGC   21.88 (-1.93%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
GE   12.25 (-2.23%)
TSLA   901.00 (+0.18%)
AMD   53.28 (-6.97%)
T   38.55 (-0.16%)
ACB   1.67 (-0.60%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
DIS   138.97 (-1.00%)
GILD   69.70 (+4.03%)
Log in

NASDAQ:NVIV - Invivo Therapeutics Stock Price, Forecast & News

$6.90
-0.17 (-2.40 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$6.29
Now: $6.90
$7.07
50-Day Range
$0.20
MA: $1.52
$8.10
52-Week Range
$3.69
Now: $6.90
$52.14
Volume58,659 shs
Average Volume78,465 shs
Market Capitalization$3.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$51.99 per share

Profitability

Net Income$-23,420,000.00

Miscellaneous

Employees6
Market Cap$3.80 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.


Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?

Invivo Therapeutics's stock reverse split before market open on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($224.40) EPS for the quarter, missing the Zacks' consensus estimate of ($12.30) by $212.10. View Invivo Therapeutics' Earnings History.

When is Invivo Therapeutics' next earnings date?

Invivo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Invivo Therapeutics.

Has Invivo Therapeutics been receiving favorable news coverage?

Press coverage about NVIV stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Invivo Therapeutics earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the immediate future. View News Stories for Invivo Therapeutics.

Who are some of Invivo Therapeutics' key competitors?

What other stocks do shareholders of Invivo Therapeutics own?

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the folowing people:
  • Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 70)
  • Mr. Richard C. Christopher, Chief Financial Officer (Age 49)
  • Mr. William D'Agostino PE, Sr. VP of Operations

Who are Invivo Therapeutics' major shareholders?

Invivo Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (6.81%) and Renaissance Technologies LLC (4.46%). View Institutional Ownership Trends for Invivo Therapeutics.

Which institutional investors are buying Invivo Therapeutics stock?

NVIV stock was bought by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Invivo Therapeutics.

How do I buy shares of Invivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $6.86.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $3.77 million. The biotechnology company earns $-23,420,000.00 in net income (profit) each year or ($67.57) on an earnings per share basis. Invivo Therapeutics employs 6 workers across the globe.View Additional Information About Invivo Therapeutics.

What is Invivo Therapeutics' official website?

The official website for Invivo Therapeutics is http://www.invivotherapeutics.com/.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]


MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel